Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Comment by deninsaskon Dec 18, 2007 1:58pm
277 Views
Post# 14039931

HEY POLAK......More BIG $$$ Coming right away!!

HEY POLAK......More BIG $$$ Coming right away!! Polak.......Phasell Initiation Milestone Payment for ELND005 estimates from the analysts range from $5 Million to over $10 Million. Whats yer guess as to the amount........I know its a moot point with $60 Mil Cash in the Vault....... TT-223 Stand Alone has Better Results than either Byetta OR Liraglutide (Novo's STILL UNAPPROVED GLP1 Analogue) did at this stage of the game. Way better when you take into account the Nausea and vomiting that they both induce in Humans.......whereas TT-223 Does Not have ANY Nausea related adverse events in dosing up to 30mg/kg. HUGE!! Proof of Concept Proven in the TT-223+EGF Phasell Trial!! Now we can move on with way less risk in the TT-223 monotherapy Trial and the TT-223+GLP1 (Byetta the ALREADY Approved GLP1 Analogue) Phasell Trial. Second of 2 Trials for TT-223 completing SOON. First one started in Sept. already completed. TT-223 has absolutely NO adverse effect in a couple previous Phasel Trials.......So Transition had to do not just Dose-Finding in these Trials but they're pumping it in at doses way Over 30mg/kg just to find the adverse event!! Unreal. Really. GPP All
Bullboard Posts